Gregory Renza

The recent pressure on Seagen Inc.’s (NASDAQ: SGEN) stock may offer a nearer-term opportunity, but the biotech's position as an attractive strategic target is “too intriguing to ignore.” That's according to RBC Capital Markets analyst Gregory Renza who named Merck & Co...

Gilead Sciences, Inc. (NASDAQ: GILD) surged more than 16% after hours Thursday when STAT News reported promising preliminary results for a prospective COVID-19 therapy. In a trial conducted by the University of Chicago Medicine, remdesivir has been associated with rapid recovery and near-term...

On Tuesday, Jefferies issued a company note on Gilead Sciences, Inc. (NASDAQ: GILD) after an "R&D Day" showed that potential drug candidates in the hepatitis B market may prove effective. Currently, analysts at Jefferies rate Gilead as a Hold with an $100 price target. Brian Abrahams and...